Health-care issues make their way into the spotlight these days on small-cap markets in a variety of ways.
Monday is a day in which health-care issues are firing up the charts, gaining 0.7% in New York. In Canada, the advance was 1%.
Atlanta-based GeoVax Labs, Inc. (OTC: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announced today the closing over the weekend, of a private placement offering.
GOVX entered into a securities purchase agreement with an institutional investor. The Company issued the Investor convertible senior secured debentures in the aggregate principal amount of $1,200,000 (including a 12.5% original issue discount) and Warrants to purchase an aggregate of 2,400,000 shares of GOVX’s common stock.
Said CEO David Dodd, This financing will allow us to continue our work on various projects, including a COVID-19 vaccine, while we prepare for a public offering of our securities to accelerate the advancement of our product pipeline.”
Shares in GOVX prospered 17.5 cents, or 37.6%, to 64 cents during Monday’s noon hour, on volume of 854,000 shares.
Across the border, Winnipeg-based Medicure Inc. (TSX-Venture: MPH) announced that results from the investigator sponsored FABOLUS-FASTER Phase 4 clinical trial, using AGGRASTAT®, have been published in Circulation, a peer-reviewed journal of the American Heart Association.
FABOLUS-FASTER studied different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI.
MPH shares didn’t display quite the buzz of its more southerly neighbour, gaining "only" 3%, or three cents, to $1.02, on a paltry volume of 3,700 shares.
